K. Reed Clark

Biography

Dr. Clark received his B.S. in genetics and Ph.D. in molecular genetics from the Ohio State University, and was a post-doctoral fellow in gene therapy at Nationwide Children’s Hospital.Prior to joining Dimension, Dr. Clark served as director of the cGMP Clinical Manufacturing Facility and Preclinical Vector Core, and associate center director at the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. Dr. Clark also served on the faculty of the Ohio State University as a professor in the Department of Pediatrics, College of Medicine. His laboratory has made seminal discoveries in scalable AAV engineered mammalian cell lines, FPLC purification of AAV vectors and improved AAV titration approaches using qPCR and wt-AAV free reporter cell lines. He has authored more than 50 peer-reviewed publications with a focus on utilizing AAV biologics for genetic vaccination and neuromuscular indications from pre-clinical proof of concept through early phase clinical trials. Through participation in multiple translational AAV programs, Dr. Clark has garnered extensive experience with multiple AAV based biologics that have progressed to early phase clinical testing. He has served as a member on the both the AAV2 and AAV8 reference standard committees, chair of the institutional IBC, and multiple NIH and private peer review study sections. Dr. Clark received his B.S. in genetics and Ph.D. in molecular genetics from the Ohio State University, and was a post-doctoral fellow in gene therapy at Nationwide Children’s Hospital.Prior to joining Dimension, Dr. Clark served as director of the cGMP Clinical Manufacturing Facility and Preclinical Vector Core, and associate center director at the Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital. Dr. Clark also served on the faculty of the Ohio State University as a professor in the Department of Pediatrics, College of Medicine. His laboratory has made seminal discoveries in scalable AAV engineered mammalian cell lines, FPLC purification of AAV vectors and improved AAV titration approaches using qPCR and wt-AAV free reporter cell lines. He has authored more than 50 peer-reviewed publications with a focus on utilizing AAV biologics for genetic vaccination and neuromuscular indications from pre-clinical proof of concept through early phase clinical trials. Through participation in multiple translational AAV programs, Dr. Clark has garnered extensive experience with multiple AAV based biologics that have progressed to early phase clinical testing. He has served as a member on the both the AAV2 and AAV8 reference standard committees, chair of the institutional IBC, and multiple NIH and private peer review study sections.

Research Interest

His research interest in Business and Management